Memory chipmaker Micron Technology Inc. (NASDAQ: MU) on Wednesday reported stronger-than-expected earnings for the first quarter of fiscal 2026. Revenue increased 57%
Micron Q1 2026 earnings beat estimates; revenue surges 57%
Categories
Biotechnology
Pfizer affirms FY25 earnings guidance, provides full-year 2026 outlook
Pfizer Inc. (NYSE: PFE) has reaffirmed its earnings outlook for fiscal 2025 and revised revenue guidance. The pharma giant also initiated guidance
Unicycive is all-in on kidney care, focusing on underserved areas: CEO
Unicycive Therapeutics, Inc. (NASDAQ: UNCY) is a biotech firm engaged in the development of novel treatment options for patients with renal diseases.
Advantage of CERo’s CER receptor lies in native human protein-based antigen binding: CEO
CERo Therapeutics Holdings, Inc. is a biotechnology company pioneering engineered T cell immunotherapies to combat cancer, with a focus on hematologic malignancies
Viatris (VTRS) posts Q3 2025 results and updates 2025 guidance
Pharmaceuticals company Viatris Inc. (NASDAQ: VTRS) on Thursday reported financial results for the third quarter of fiscal 2025, and updated its outlook
ABBV Earnings: A snapshot of AbbVie’s Q3 2025 report
Pharmaceuticals company AbbVie, Inc. (NYSE: ABBV) on Friday reported a decline in earnings for the third quarter of fiscal 2025, despite an
BIIB Earnings: A snapshot of Biogen’s Q3 2025 results
Biotechnology firm Biogen Inc. (NASDAQ: BIIB) reported an increase in adjusted profit for the third quarter of 2025 when its revenues remained
Earnings Summary: A snapshot of Revvity’s (RVTY) Q3 2025 report
Revvity, Inc. (NYSE: RVTY), a provider of health science solutions and technologies, reported a decline in adjusted earnings for the third quarter
Infographic: How Thermo Fisher (TMO) performed in Q3 2025
Thermo Fisher Scientific Inc. (NYSE: TMO) reported its third quarter 2025 earnings results today. Revenue grew 5% year-over-year to $11.12 billion. Organic
Kairos Pharma’s goal is to intervene early in resistance and re-sensitize cancer cells to therapy: CEO
Kairos Pharma, Ltd. (NYSE: KAPA) is a biopharma company developing a pipeline of targeted therapies for cancer patients with high unmet medical
IPO News: MapLight Therapeutics targets $704 mln valuation in Nasdaq debut
In recent months, Wall Street has seen a surge of healthcare firms seeking to go public, as IPO activity continues to regain
Strategic partnerships have been essential to Profusa’s progress: CEO Ben Hwang
Profusa, Inc. (NASDAQ: PFSA) is a digital health company pioneering a new generation of biointegrated sensors. Its injectable biosensors are designed to
Eli Lilly (LLY) set to report Q2 2025 results. Here’s what to expect
Eli Lilly and Company (NYSE: LLY) had a positive start to fiscal 2025, reporting strong revenue and earnings growth for the first
BIIB Earnings: Highlights of Biogen’s Q2 2025 results
Biotechnology firm Biogen Inc. (NASDAQ: BIIB) on Thursday reported higher revenues and adjusted profit for the second quarter of 2025. The company
Bristol Myers Squibb (BMY) Earnings: 2Q25 Key Numbers
Bristol Myers Squibb (NYSE: BMY) reported its second quarter 2025 earnings results today. Total revenues inched up 1% year-over-year to $12.3 billion.
Plus Therapeutics CEO: Lead candidate REYOBIQ demonstrates strong safety and efficacy in early trials
Plus Therapeutics (NASDAQ: PSTV) is a pharmaceutical company engaged in the development of targeted radiotherapeutics for difficult-to-treat cancers. Currently, it is advancing
BIIB Earnings: Biogen Q1 2025 adj. profit drops despite higher revenues
Biotechnology firm Biogen Inc. (NASDAQ: BIIB) Thursday reported a year-over-year decrease in adjusted profit for the first quarter of 2025, despite an
Infographic: How Eli Lilly (LLY) performed in Q1 2025
Eli Lilly and Company (NYSE: LLY) reported its first quarter 2025 earnings results today. Worldwide revenue was $12.73 billion, up 45% compared
AbbVie Q1 2025 adjusted earnings increase on 8% revenue growth; beat estimates
Biopharmaceutical company AbbVie, Inc. (NYSE: ABBV) announced first-quarter 2025 financial results, reporting an increase in revenue and adjusted earnings. The company reported
Bristol-Myers Squibb swings to profit in Q1 2025; revenue drops
Bristol Myers Squibb (NYSE: BMY) reported net profit for the first quarter of 2025, compared to a loss last year. The biotechnology
MRK Earnings: Merck & Co. Q1 adj. profit rises, beats estimates
Merck & Co. Inc. (NYSE: MRK) Thursday reported an increase in adjusted earnings for the first quarter of 2025, while the pharma